BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, January 10, 2025
See today's BioWorld
Home
» Young blood's elixir: Alkahest draws $38M from Grifols to battle CNS disorder
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Young blood's elixir: Alkahest draws $38M from Grifols to battle CNS disorder
March 16, 2015
By
Michael Fitzhugh
No Comments
Betting on the restorative power of young blood to reverse cognitive decline in Alzheimer's disease and other central nervous system disorders, Grifols SA is taking a 45 percent stake in Stanford University spinout Alkahest Inc.
BioWorld